November 12, 2024

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Read more

Together,
we can reach higher ground

At Climb Bio, we believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients living with immune-mediated diseases.

November 12, 2024

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Read more

Experienced team

At Climb Bio, our team has a knack for seeing what no one else sees—and a drive to achieve results no one expects.

Elevating possibilities

Our pipeline is focused on immune-mediated diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases.

STAGE OF DEVELOPMENT
Indication(s)
Pre-Clinical
Phase 1
Phase 2
Phase 3

CANDIDATE

Budoprutug

Anti-CD19
Fc-engineered, monoclonal antibody

Indications

Membranous Nephropathy

Phase 1

Systemic Lupus Erythematosus

Phase 1

Immune Thrombocytopenia*

Phase 1

*Subject to investigational new drug application clearance

Commitment to patients

We only have one life to live. At Climb, we all feel the urgency to give everyone living with an immune-mediated disease more quality time—and less time thinking of themselves as a patient.

Come climb with us

Here you’ll find good people. Smart people. Curious people. Our team has a diversified past, a singular focus on the now, and an unshakeable commitment to a better future.

OPEN POSITIONS:

There are currently no open positions.